NASDAQ: APREAprea Therapeutics Inc Stock
$5.27-0.32 (-5.72%)
Updated May 17, 2024
APRE Price
$5.27
Fair Value Price
$7.13
Market Cap
$28.62M
52 Week Low
$2.78
52 Week High
$8.85
P/E
-1.59x
P/B
0.99x
P/S
29.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$963.80k
Earnings
-$12.72M
Gross Margin
100%
Operating Margin
-1,449.27%
Profit Margin
-1,319.5%
Debt to Equity
0.15
Operating Cash Flow
-$13M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APRE Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APRE ($5.27) is undervalued by 26.13% relative to our estimate of its Fair Value price of $7.13 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APRE ($5.27) is significantly undervalued by 26.13% relative to our estimate of its Fair Value price of $7.13 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APRE due diligence checks available for Premium users.
Be the first to know about important APRE news, forecast changes, insider trades & much more!
APRE News
Valuation
APRE fair value
Fair Value of APRE stock based on Discounted Cash Flow (DCF)
Price
$5.27
Fair Value
$7.13
Undervalued by
26.13%
APRE ($5.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APRE ($5.27) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.59x
Industry
8.47x
Market
30.97x
APRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
6.01x
APRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APRE's financial health
Profit margin
Revenue
$380.6k
Net Income
-$2.8M
Profit Margin
-738.4%
APRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$33.2M
Liabilities
$4.3M
Debt to equity
0.15
APRE's short-term assets ($33.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APRE's short-term assets ($33.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
-$8.0k
Financing
$14.7M
APRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APRE vs Biotech Stocks
Aprea Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.